Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients
Inventors
PARK, Sea Gwang • ROH, Kug Hwan • KIM, Hyun Woong • Park, Sung Jae
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11197918-B2
Publication Date
2021-12-14
Expiration Date
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
Core Innovation
The invention describes a pharmaceutical composition and a method of treating an ocular neovascular disease in a subject in need thereof. The pharmaceutical composition comprises collagen type I and a 34-mer pigment epithelium derived factor (PEDF) peptide consisting of SEQ ID NO: 1 as an active ingredient. The 34-mer PEDF peptide is present in the composition, and collagen type I maintains an intraocular antiangiogenic effect of the PEDF peptide.
Combining collagen type I with the 34-mer PEDF peptide enhances or maintains the antiangiogenic activity of the PEDF 34-mer. The combination extends the effective dosage range and prolongs antiangiogenic activity, thereby reducing the need for frequent administration compared with peptide alone. It also describes formulation flexibility for ocular administration.
The pharmaceutical composition is formulated as eye drops, ophthalmic gel/ointment, or injection, using a pharmaceutically acceptable carrier. Supporting results are described using in vitro HUVEC tube formation and in vivo laser-induced choroidal neovascularization in a mouse model, with comparisons of collagen type I plus 34-mer PEDF peptide versus the peptide alone. The invention also reports mechanistic observations involving JNK/ERK, Akt, and Wnt/beta-catenin signaling pathways and reports formulation/ocular compatibility based on light transmittance and mixture stability during storage.
Claims Coverage
The document provides one independent claim, with multiple dependent claims that specify sources, concentrations/amounts, disease subtype selection, and dosage forms, centered on maintaining an intraocular antiangiogenic effect by combining collagen type I with a 34-mer PEDF peptide (SEQ ID NO: 1).
Treating ocular neovascular disease with collagen type I maintaining intraocular antiangiogenic effect of 34-mer PEDF
A method of treating an ocular neovascular disease in a subject in need thereof by administering a pharmaceutical composition comprising collagen type I and a 34-mer pigment epithelium derived factor (PEDF) peptide consisting of SEQ ID NO: 1, wherein the 34-mer PEDF peptide has a concentration of 0.2-50 pmol/ml and the collagen type I maintains an intraocular antiangiogenic effect of the PEDF peptide.
Across the claim set described, the core coverage is the co-administration concept: a pharmaceutical composition containing collagen type I and a 34-mer PEDF peptide (SEQ ID NO: 1), with collagen type I maintaining the intraocular antiangiogenic effect of the PEDF peptide to treat ocular neovascular disease, while dependent claims further restrict component origin/amounts, disease subtypes, and ocular dosage forms.
Stated Advantages
Maintains or enhances the antiangiogenic activity of the PEDF 34-mer when combined with collagen type I.
Extends the effective dosage range of the 34-mer PEDF peptide.
Prolongs antiangiogenic activity to reduce dosing frequency compared with peptide alone.
Reduces side effects associated with frequent injections.
Enables ocular formulation as eye drops, ophthalmic gel/ointment, or injection.
Reports suitability via light transmittance and mixture stability over storage conditions.
Documented Applications
Treatment of ocular neovascular diseases, including corneal neovascular disease, diabetic retinopathy, choroidal neovascular disease, and age-related macular degeneration.
Administration in ocular dosage forms including eye drops, ophthalmic gel/ointment, and injection.
Use of in vitro and in vivo models for evaluating antiangiogenic activity, including HUVEC tube formation and a laser-induced choroidal neovascularization mouse model.
Prophylactic and treatment settings are described for therapeutic effect in the context of ocular neovascularization.
Interested in licensing this patent?